Torrens, GabrielCabot, GabrielOcampo-Sosa, Alain AConejo, M CarmenZamorano, LauraNavarro, FerranPascual, AlvaroMartinez-Martinez, LuisOliver, Antonio2023-01-252023-01-252016-09-23Torrens G, Cabot G, Ocampo-Sosa AA, Conejo MC, Zamorano L, Navarro F, et al. Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6407-10.http://hdl.handle.net/10668/10328The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.enAzabicyclo CompoundsDrug CombinationsMeropenemPseudomonas aeruginosabeta-Lactam ResistanceCeftazidimeHumansMicrobial Sensitivity TestsThienamycinsresearch article27480848Restricted AccessCeftazidimaMeropenemEsguinces y distensionesPseudomonas aeruginosaLactamasResistencia a múltiples medicamentosEstudio multicéntricoSepsis10.1128/AAC.01282-161098-6596PMC5038310https://europepmc.org/articles/pmc5038310?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038310/pdf